

# Welcome to the COVID-19 Provider Webinar


Friday, September 15, 2023

9:00AM – 10:30AM



# Questions

**During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.**



**Resource links will be  
dropped into, “Chat”**



# Housekeeping

## Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

## Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at:  
[EZIZ COVID Education](#)



If you have post-webinar questions, please email [leslie.amani@cdph.ca.gov](mailto:leslie.amani@cdph.ca.gov)

# Agenda: Friday, September 15, 2023

No.	Item	Speaker	Time (AM)
1	Welcome and Announcements	Leslie Amani (CDPH)	9:00 – 9:05
2	Vaccine Administration Data	Celeste Romano (CDPH)	9:05 – 9:10
3	<b>CA COVID-19 Vaccination Program Close-out</b>	Alan Hendrickson and Leslie Amani (CDPH)	9:10 – 9:15
4	<b>Updated COVID-19 Vaccine</b>	Caterina Liu, MD and Katherine McHugh (CDPH)	9:15 – 9:25
5	<b>COVID-19 Vaccine Access: Commercialization/BAP/VFC</b>	Claudia Aguiluz and Edward Salaguinto (CDPH)	9:25 – 9:40
6	Vaccine Management	Josh Pocus (My Turn) and Maria Volk (myCAvax)	9:40 – 9:50
7	Pharmacy COVID-19 Therapeutics Updates	Edward Salaguinto, PharmD, RPh (CDPH)	9:50 – 9:55
8	Resources and Q&A	CDPH Subject Matter Experts	9:55 – 10:30

**Thank you, California COVID-19 Vaccination Program Providers!**

# Announcements

Leslie Amani, CDPH



# CDC COCA Call

Topic: Preparing for the Upcoming Respiratory Virus Season: Recommendations for Influenza, COVID-19, and RSV Vaccines for Older Adults

When: Tuesday, September 19, 2023

Time: 11AM – 12PM

No Registration needed.

Zoom meeting link to join [here](#)

During this COCA Call, CDC presenters will provide updates about the latest recommendations and clinical considerations for administering influenza, COVID-19, and RSV vaccines to adults 60 years and older and discuss resources and communication strategies that may help facilitate older adult vaccination.

[CDC Emergency Preparedness and Response Webpage](#)



# Upcoming COVID-19 Crucial Conversations Webinar

**Topic:** Talking with Patients about the Updated COVID-19 Vaccine

**Description:** Learn conversation methodologies for effectively talking with patients about the updated 2023-2024 monovalent COVID-19 vaccine.

**Speaker:** Dr. Alex McDonald, cofounder of #ThisIsOurShot

**When:** Wednesday, September 27 at 12:00PM - 1:00PM PT

[Register here!](#)



The graphic is a blue rectangular poster with white and orange text boxes. At the top right is the California Department of Public Health logo. A large orange speech bubble at the top left contains the text 'COVID-19 Crucial Conversations'. Below it, a white box with an orange border contains the text 'Upcoming Webinar: Talking with Patients about the Updated COVID-19 Vaccine'. Underneath this box, smaller text reads 'Learn conversation methodologies for effectively talking with patients about the updated monovalent COVID-19 vaccine.' and 'Wednesday, September 27 12:00PM - 1:00PM PT'. At the bottom of this white box is an orange button that says 'Register here!'. To the right of the text is a circular portrait of Dr. Alex McDonald, a man with glasses and a white lab coat. Below the portrait are two purple circular icons: one with the text '#THIS IS OUR SHOT' and another with '#VACU NATE YA'.

**COVID-19 Crucial Conversations**

California Department of Public Health

**Upcoming Webinar:**  
**Talking with Patients about the Updated COVID-19 Vaccine**

Learn conversation methodologies for effectively talking with patients about the updated monovalent COVID-19 vaccine.

**Wednesday, September 27**  
**12:00PM - 1:00PM PT**

**Register here!**

#THIS IS OUR SHOT #VACU NATE YA



# Current Issues in Immunization Webinar

**Topic:** CDC Clinical Guidance for Use of Products to Prevent RSV Disease in Infants

**When:** Wednesday, September 27, 2023

**[Webinar information can be found here.](#)**

Immunization Webinars are 1-hour presentations with Q&A included. Internet access is needed to participate.

These presentations, collectively titled “Current Issues in Immunization,” are scheduled 4 to 5 times per year.

Each presentation is presented by the National Center for Immunization and Respiratory Diseases and designed to provide clinicians with the most up-to-date information on immunization.





# Archived: Afternoon TEAch Webinar What's New with COVID-19, Flu, and RSV?

This week, CDPH held an [Afternoon TEAch](#) webinar that covered:

- Updates on COVID-19 Vaccine Formulation and Recommendations for Children
- Updated CDC ACIP Recommendations for Flu and RSV
- Transition of COVID-19 Vaccines to VFC Program


View [slides](#) and watch [recording](#).



# CDPH Resources

## Updated Flu, COVID-19, RSV Job Aids












- [Pediatric/Adult Influenza Vaccine Guide](#) (IMM-859)
- [VFC Flu Usage Log](#) (IMM-1053)
- [Block Timing Schedule](#) (IMM-395) | [Spanish](#)

Immunization Timing 2023											
Suggested schedule to meet recommendations on time. Refer to web version.											
Birth											
HepB <sup>1</sup>											
RSV <sup>2</sup> (age: 0-8 months)											
6 months – 18+ years											
COVID-19 vaccine(s) <sup>3</sup>						Flu vaccine, every fall <sup>4</sup>					
Age 2 months	Interval from previous dose	Age 4 months	Interval from previous dose	Age 6 months	Interval from previous dose	Age 12 months	Interval from previous dose	Age 15 months	Interval from previous dose	Age 18 months	Interval from previous dose
DTaP (Diphtheria, Tetanus, Pertussis)		DTaP	1-2 months	DTaP	1-2 months	HepA <sup>5</sup> (age: 12-23 months)		DTaP <sup>12</sup>	6-12 months	HepA	6-18 months
Polio (IPV)		Polio (IPV)	1-2 months	Polio	1-14 months	MMR <sup>13,14</sup> (ages: 12-15 months)					
HepB <sup>3</sup> (age: 1-2 months)	1-2 months after birth dose	HepB <sup>3</sup> (if 1st dose given at 2 months)	1-2 months	HepB <sup>3</sup> (age: 5-18 months)	2-12 months and 24 months after 1st dose	Var <sup>15</sup> (age: 12-15 months)					
Hib (Hib meningitis)		Hib	1-2 months	Hib <sup>5</sup>	1-2 months	Hib (age: 12-15 months)	2-8 months				
PCV (Pneumo)		PCV	1-2 months	PCV	1-2 months	PCV <sup>11</sup> (age: 12-15 months)	6-8 weeks				
RV <sup>6</sup> (Rotavirus)		RV <sup>6</sup>	4-10 weeks	RV <sup>6</sup>	4-10 weeks						
 <b>California Kids</b> Love them. Immunize them.											
California Department of Public Health, Immunization Branch • EZIZ.org IMM-395 (9/23)											

[Block Timing Schedule \(IMM-395\)](#)

2023-2024 FLU USAGE LOG VACCINES FOR CHILDREN (VFC) PROGRAM							
INSTRUCTIONS: Keep this log near your vaccines. Fill in today's date, patient info and then make a check for each vaccine administered. Upon completion of this form, count the number of checks for each vaccine and write in the Usage Period Total. VFC flu vaccine usage since the previous order and current flu vaccine inventory must be reported with each vaccine order. File all usage logs for 3 years.		PIN: _____		Usage Period: ____/____ to ____/____			
Today's Date	Patient Name (or medical record)	Date of Birth	Fluarix <sup>®</sup> 0.5 mL syringe	FluLaval <sup>®</sup> 0.5 mL syringe	Fluzone <sup>®</sup> 0.5 mL syringe	Flumist <sup>®</sup> 0.2 mL sprayer	Flucelvax <sup>®</sup> 0.5 mL syringe
1.							
2.							
3.							
4.							
5.							
6.							
7.							
8.							
9.							
10.							
11.							
12.							

[VFC Flu Usage Log \(IMM-1053F\)](#)

PEDIATRIC/ADULT INFLUENZA VACCINE		2023-2024
6 MONTHS & OLDER	 <b>Fluarix<sup>®</sup> Quadrivalent</b> GlaxoSmithKline Biologicals 0.5 mL single-dose syringe	 <b>FluLaval<sup>®</sup> Quadrivalent</b> GlaxoSmithKline Biologicals 0.5 mL single-dose syringe
	 <b>Flucelvax<sup>®</sup> Quadrivalent</b> Seqirus 0.5 mL single-dose syringe	 <b>Fluzone<sup>®</sup> Quadrivalent</b> Sanofi Pasteur, Inc. 0.5 mL single-dose
	 <b>Afluria<sup>®</sup> Quadrivalent</b> Seqirus 0.5 mL single-dose syringe	 <b>Fluzone<sup>®</sup> Quadrivalent</b> Sanofi Pasteur, Inc. 0.5 mL single-dose vial
3 YEARS & OLDER	 <b>Afluria<sup>®</sup> Quadrivalent</b> Seqirus 5.0 mL multi-dose vial <sup>*</sup>	 <b>Fluzone<sup>®</sup> Quadrivalent</b> Sanofi Pasteur, Inc. 5.0 mL multi-dose vial <sup>*</sup>
	 <b>Flucelvax<sup>®</sup> Quadrivalent</b> Seqirus 5.0 mL multi-dose vial <sup>*</sup>	
2-49 YEARS OLD & HEALTHY	 <b>FluMist<sup>®</sup> Quadrivalent</b> MedImmune Vaccines, Inc. 0.2 mL single-dose nasal sprayer	
18 YEARS & OLDER	 <b>FluBlok<sup>®</sup> Quadrivalent</b> Protein Sciences 0.5 mL single-dose syringe	
	 <b>Fluzone<sup>®</sup> High-Dose Quadrivalent</b> Sanofi Pasteur, Inc. 0.7 mL single-dose syringe	

**STORE ALL INFLUENZA VACCINES IN THE REFRIGERATOR.**

**VFC Questions:**  
Call 877-2GET-VFC (877-243-8832)

Children under 9 years of age with a history of fewer than 2 doses of influenza vaccine are recommended to receive 2 doses this flu season. See [CDC Website](#).

Vaccines available through the Vaccines for Children Program in 2023-24 should only be used for VFC-eligible children 18 years of age or younger.

\* Multi-dose flu vaccines, which contain thimerosal, should NOT be given to pregnant women and children under 3 years of age unless Secretary of the Health and Human Services Agency issues an exemption (CA Health & Safety Code 124172).

<sup>65+</sup> Preferred vaccine product for persons 65 or older. If not available, any other age-appropriate inactivated product may be given.

California Department of Public Health

IMM-859 (8/23)

[Pediatric/Adult Flu Vaccine Guide \(IMM-859\)](#)

# CDPH Resources (continued)

## Provider Resources


- [COVID-19 Clinical Talking Points for Providers](#) (IMM-1431)
- [VFC Flu Vaccine Page](#) (EZIZ)

## Promotional Materials

- [Who needs a flu vaccine? poster](#) (IMM-782)
- [Flu & Respiratory Disease Materials](#) (EZIZ)

## Vaccine Communication Toolkits

- [Don't Wait Vaccinate Toolkit](#) (CDPH)
- [Fight Flu. Get Vaccinated Toolkit](#) (CDPH)
- [Don't Wait Vaccinate Flu Toolkit](#) (CIC)



# Digital Vaccine Record

## GET YOUR DIGITAL VACCINE RECORD



Private. Convenient. Secure.

**What is a Digital Vaccine Record (DVR)?**  
Your Digital Vaccine Record (DVR) is an electronic vaccination record from the California Immunization Registry (CAIR) and is an official record of the state of California.

**What information does the DVR include?**  
The DVR has your name, date of birth, vaccination dates, and the vaccines you received.

**Where do I access my Digital Vaccine Record?**  
Visit [myvaccinerecord.cdph.ca.gov](https://myvaccinerecord.cdph.ca.gov) to access your record. You will need to enter your first and last name, date of birth, and mobile number or email address. You will create a PIN which will be required to obtain your DVR when the link to your record is provided to you.


For more DVR questions, visit [myvaccinerecord.cdph.ca.gov/faq](https://myvaccinerecord.cdph.ca.gov/faq) or call 1-833-422-4255 (open M-F 8AM-8PM, SA-SU 8AM-5PM).

California Department of Public Health, Immunization Branch

IMM-1461 (3/9/23)

## DVR Fact Sheet

## OBTENGA SU REGISTRO DIGITAL DE VACUNACIÓN



PRIVADO. CONVENIENTE. SEGURO.

**Registro Digital de Vacunación (DVR)**  
Su Registro Digital de Vacunación (DVR, por sus siglas en inglés) es un registro electrónico de vacunación procedente del Registro de Vacunación de California (CAIR, por sus siglas en inglés) y es un registro oficial del estado de California.

**¿Qué información incluye el DVR?**  
El DVR tiene su nombre, fecha de nacimiento, fechas de vacunación y las vacunas que recibió.

**¿Dónde accedo mi Registro Digital de Vacunación?**  
Visite [myvaccinerecord.cdph.ca.gov](https://myvaccinerecord.cdph.ca.gov) para acceder su registro. Necesita ingresar su primer nombre y apellido, fecha de nacimiento y número de celular o correo electrónico. Necesitará crear un PIN para poder obtener su DVR cuando se le proporcione el enlace a su registro.

**¿Qué registros digitales puedo acceder desde el Portal DVR?**  
Hay dos tipos de registros a los que puede acceder desde el Portal DVR:

- **Código QR de COVID-19** que (cuando es escaneado por un lector de tarjetas SMART Health) mostrará la misma información que su tarjeta de papel de los CDC: su nombre, fecha de nacimiento, fechas de vacunación y las vacunas.
- **Registro de todas las vacunas** que informaron las farmacias y otros proveedores de salud a CAIR. Tome en cuenta que es posible que su historial de vacunación no se haya ingresado a CAIR.

Para más preguntas sobre el DVR, visite [myvaccinerecord.cdph.ca.gov/faq-es/](https://myvaccinerecord.cdph.ca.gov/faq-es/) o llame al 1-833-422-4255 (L—V 8AM-8PM, S-D 8AM-5PM).

California Department of Public Health, Immunization Branch

IMM-1461S (3/30/23)

## Spanish Version

- To access their DVR, patients should visit the [Digital Vaccine Record \(DVR\) portal](https://myvaccinerecord.cdph.ca.gov) ([myvaccinerecord.cdph.ca.gov](https://myvaccinerecord.cdph.ca.gov))
- Flyers are also available in [Arabic](#), [Simplified Chinese](#) and [Traditional Chinese](#), [Korean](#), [Tagalog](#) and [Vietnamese](#).
- The DVR request form is also available in the languages listed above to support easy communication. Records are also printable in these languages! See our [DVR FAQs](#) for more information.




# Request for Photos from Providers

CDPH wants to celebrate all LHDs and Providers who have contributed so much to the California COVID-19 Vaccination Program.

Please email any staff photos to [leslie.amani@cdph.ca.gov](mailto:leslie.amani@cdph.ca.gov) by **TODAY, Friday, September 14, 2023.**




# Friday Provider Webinar Transition Timeline



\*Provider webinar cadence subject to change

# Change! Transitions! New information!

Select the numbered dog photo that best describes your current feelings.



# Vaccine Administration Data

Celeste Romano, CDPH




# Vaccine Administration Summary

as of September 11, 2023

**89,809,381**

Total Doses Administered:


Daily Doses Administered: **Statewide**



**8,585,198**

Total Up-to-Date Recipients:

Percent of Population Who Are Up-to-Date




# Trends in Vaccine Administration\*

as of September 11, 2023

## Week-to-Week Trends

Highest uptake among 65+ and Under 5

Slight decrease in uptake among all age groups in anticipation of new monovalent mRNA vaccine



\*Estimates are approximations based on comparison of vaccination data to DOF 2021 population estimates

# Up-to-Date Status by Race/Ethnicity\*


as of September 11, 2023

## Demographic Trends

Highest uptake among Asian and White populations

Over half of those in each race/ethnicity group have completed their primary series but are not Up-to-Date

Race/Ethnicity: % of Population by Vaccine Status: Up To Date | Not Up To Date | No Shots



\*Vaccination rate estimates for some groups, such as NHPI, may be affected by differences in how demographic data is collected by the Census and at the time of vaccination

# Up-to-Date Status Among 50+ by HPI\*


as of September 11, 2023

## Intersection of Age and HPI

Highest uptake in 65+ and Healthiest Places Index Q4

Up-to-Date status varies across age and HPI with wider variation within the 65+ vs 50-64

Percent of 50+ Population Who Are Up-to-Date by HPI and Age



\*Estimates are approximations based on comparison of vaccination data to DOF 2021 population estimates

# Up-to-Date Status Among 65+ by County


as of September 11, 2023

## Geographic Trends

Uptake varies geographically,

Highest rates in coastal counties

Ranges from **18.2%-66.6%** of 65+ population



# Data Summary

as of September 11, 2023

## Key Metrics

**89.8 million** doses administered

| **+27K** doses administered

**21.5%** Statewide Up-to-Date

| **8.6 million** Up-to-Date recipients

**19%** difference in Up-to-Date across Race/Ethnicity groups

## System Notes

- Preparing for inclusion of new monovalent mRNA into snowflake tables
  - Metrics for new monovalent mRNA vaccine to be made available pending system updates- TBD
- Email [cdphvaccinatedatateam@cdph.ca.gov](mailto:cdphvaccinatedatateam@cdph.ca.gov) for questions and comments

# CA COVID-19 Vaccination Program Close-out



# What to Do with Bivalent Pfizer & Moderna Products

- Quarantine deauthorized mRNA products to prevent administration errors!
- Report vaccine products as “Waste” in myCAvax and use “Other” to add comment “deauthorized”!
- Already marked inactive? Inactive locations can now report as of 9/12/23!
- Dispose of vaccines following practice protocols; vaccines may be disposed of in a pharmaceutical waste container, or a comingled pharmaceutical/Sharps waste container.
- Waste Reporting Deadline: Saturday, September 30, 2023, by 11:59PM


Manufacturer	Presentation	Unit of Sale NDC
ModernaTX Inc.	MDV5; 10-pack	80777-0282-99
ModernaTX Inc.	Ped 6m-5y; MDV2; 10pk	80777-0283-99
Pfizer Inc.	MDV6; 10-pack	59267-0304-02
Pfizer Inc.	SDV; 10pk	59267-1404-02
Pfizer Inc.	Ped 5y-11y; MDV10; 10pk	59267-0565-02
Pfizer Inc.	Ped 6m-4y; MDV10; 10pk	59267-0609-02

**Continue to administer Novavax  
until the product is deauthorized!**





# myCAvax Waste Reporting Close-out Timeline



Waste Reporting Deadline:  
September 30, 2023  
11:59PM

“Starting strong is good. Finishing strong is epic!”

Robin Sharma



# What to do with old ancillary supplies?

- Check if ancillary supplies are expired.
- If supplies are expired, dispose of them according to your clinic's waste management policies.
- If supplies are not expired, you can use them for other clinical activities, give them to other providers, or dispose of them
  - **Do not** send them out of the country!
- Shred old CDC COVID-19 vaccination cards.
- If you should need additional ancillary supplies, we “know a guy”...aka “The TPR”.





# Deauthorized COVID-19 Vaccine Inventory Checklist

- Remove deauthorized products immediately to prevent administration errors.
- For deauthorized bivalent products: Report as “Waste” and use “Other” to add comment “deauthorized”; dispose of products following practice protocols (may be disposed of in a pharmaceutical waste container, or a comingled pharmaceutical/Sharps container).
- For nonviable updated COVID-19 vaccine: Report as “Waste” and return to McKesson; label as “nonviable vaccine”.

Managing Vaccine Inventory

### About Inventory Management

Efforts to raise immunization levels in provider populations fall short if vaccine inventory is not managed to ensure viability. Vaccine inventory management is an essential practice that can prevent inadvertent vaccine loss due to temperature excursions.

### Inventory Checklist

Inventory management tasks will quickly become part of your practice protocols to protect vaccines and minimize patient revaccination. Use this checklist to get started.

#### Store Vaccine under Recommended Temperatures

- ❑ Don't reject shipments; report shipment incidents in myCAvax the same day for resolution.
- ❑ Store vaccines under [manufacturer-recommended temperatures](#); label cartons with beyond-use dates as recommended by vaccine manufacturers.
- ❑ Group adult vaccines together and label in large letters (cartons, baskets, or shelf space) to ensure correct products are removed for administration.
- ❑ Record storage unit temperatures twice daily on a temperature log with current, min and max readings, or use [COVID-19 log](#); report temperature excursions daily in myCAvax.

#### Manage Expiration & Beyond-Use Dates

- ❑ Remove deauthorized products immediately to prevent administration errors.
- ❑ Rotate stock weekly (and when new shipments arrive) to ensure vaccines soon to expire are used first.
- ❑ As expiration dates draw near, check for extensions using Moderna | Novavax | Pfizer-BioNTech (TBD) expiry lookup tools; label product with updated dates to prevent errors.
- ❑ If unable to use before expiration, contact your local health department about transfers.
- ❑ Strictly comply with the manufacturer guidance on expiration dates.
- ❑ Remove spoiled or expired vaccine IMMEDIATELY to prevent administration errors.
- ❑ Do not use vaccine after the earlier of expiration or use-by date.

#### Report Vaccine Wastage

- ❑ Report doses spoiled, expired, or wasted in myCAvax.
- ❑ For deauthorized bivalent products: Report as “Waste” and use “Other” to add comment “deauthorized”; dispose of products following practice protocols (may be disposed of in a pharmaceutical waste container, or a comingled pharmaceutical/Sharps container).
- ❑ For nonviable 2023-24 COVID-19 vaccine: Report as “Waste” and return to McKesson; label as “nonviable vaccine”.

9/14/23

## CDPH Inventory Checklist

27

# Update!

Provider Resources on [eziz.org/covid](https://eziz.org/covid)

Content is migrating to <https://eziz.org/>

## California's Vaccine Programs



California  
Vaccines for  
Children Program

VFA

California  
Vaccines for  
Adults Program

BAP

California  
Bridge Access  
Program

317

Local Health  
Departments

- Hot Topics
- BAP Program Enrollment
- VFC (Vaccines for Children)
- VFA (Vaccines for Adults)
- 317
- Education & Support Materials
- More to explore!

Vaccinate ALL 58 California COVID-19 Vaccination Program

ENHANCED BY Google

**Program Updates**

**Program Enrollment**

**My Turn**

**Vaccine Management**

**Vaccine Administration**

**Reporting Requirements**

**Archived Communications**

**Patient Resources**

**Provider Call Center**

Contact us for questions about vaccine orders, account updates, help with accessing documents, and more.

Phone: (833) 502-1245  
Hours: Mon-Fri, 8AM-5PM

Email:  
[Program Info](#)  
[myCAvax Technical Support](#)  
[MyTurn Technical Support](#)

**My Turn Clinic Translation Line:**  
(833) 980-3933  
Mon-Fri: 8AM-5PM

**Vaccines**

[Manufacturer Contacts](#)

**Updates for Providers**

FAQs

Provider Webinars

Crucial Conversations

Training Calendar

**Alerts:**

**COVID-19 Vaccine Commercialization Resources**

- [COVID-19 Vaccine Commercialization FAQs](#) Updated 9/1
- [Commercialization at a Glance: Provider Transition Guide](#) Updated 9/1
- [U.S. Dept of Health and Human Services \(HHS\) COVID-19 Commercialization](#) 7/13
- [CDC Bridge Access Program Guide](#) 7/13

**Vaccine Updates**

- Important: COVID-19 Vaccine Timeline Change **NEW** 8/31
- August and September COVID-19 Vaccine Expiration Dates 8/4
- Shelf-Life Extension for Moderna COVID-19 Lots 8/3

**Clinical Job Aids**

- [COVID-19 Vaccine Products Guide](#), Updated 8/4
- [COVID-19 Vaccination Schedule \(Timing Guide\)](#), Updated 6/9
- [Calendario de la Vacuna COVID-19 \(Spanish Timing Guide\)](#), Updated 5/15
- [Moderna Vaccine 6 Months - 5 Years: When to Use Blue or Pink Cap](#), 5/10

**COVID-19 Treatments**

- For information regarding COVID-19 treatments, please visit the [CDPH Therapeutics Webpage](#)

COVID19.ca.gov | View CDPH's privacy policy



# 2023-2024 Updated COVID-19 Vaccine



# Clinical Update

Caterina Liu, M.D., CDPH



# 2023-24 Updated COVID-19 Vaccine Recommendation

- Everyone 6 months and older should get an updated 2023-2024 COVID-19 vaccine.
- Updated formulation contains XBB.1.5 (Omicron subvariant) and are a better match for currently circulating COVID-19 strains.
- Vaccination remains the best protection against COVID-19-related hospitalization and death. Vaccination can also reduce the chance of suffering the effects of Long COVID.
- COVID-19 vaccines are safe and hundreds of millions of people have safely received a COVID-19 vaccine in the U.S.
- Bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.



# CDC COVID-19 Updated (Monovalent XBB) Vaccine Summary

- **Effectiveness**

- Monovalent XBB containing COVID-19 vaccines increase the immune response against the currently circulating variants
- Last year's updated vaccine was effective at preventing medically attended COVID-19, hospitalization due to COVID-19, and death due to COVID-19
- Accumulating evidence that COVID-19 vaccination reduces post-COVID conditions among both children and adults

- **Safety**

- COVID-19 vaccines have a high degree of safety
- Rare events of myocarditis and anaphylaxis have been seen in post-authorization studies; unlikely that updating the formulation would increase adverse event rates

- **Risk vs. Benefits**

- Benefits are anticipated in all age groups; benefits of COVID-19 vaccines vary by age and incidence of COVID-19 hospitalizations
- Benefits outweigh risks in age groups for which risk of myocarditis is highest
- Modeling projects more hospitalizations and deaths averted when updated doses are universally recommended compared to no recommendation or recommended only for persons ≥65 years





# CDC Proposed 2023-2024 mRNA COVID-19 Vaccine Recommendations

- Everyone ages 5 years and older is recommended to receive 1 dose of a 2023–2024 mRNA COVID-19 vaccine
- Children ages 6 months–4 years should complete a multi-dose initial series (2 doses of Moderna or 3 doses of Pfizer-BioNTech mRNA COVID-19 vaccine) with at least one dose of the 2023–2024 COVID-19 vaccine
- People who are moderately or severely immunocompromised should complete a 3- dose initial series with at least one dose of the 2023–2024 COVID-19 vaccine and may receive 1 or more additional 2023–2024 COVID-19 vaccine doses
- Novavax
  - The original Novavax COVID-19 vaccine remains authorized for use as a 2-dose primary series and can be given as a booster dose in limited situations
  - Authorizations or approvals for 2023-2024 Novavax COVID-19 vaccine will be determined by FDA, with CDC recommendations to follow



Bivalent recommendations	Proposed 2023 – 2024 vaccine recommendations	Rationale
Everyone ages <b>6 years</b> and older recommended for a single bivalent dose	Everyone ages <b>5 years</b> and older recommended for a single 2023 – 2024 dose	Eliminates complex recommendations for 5-year-olds
Two Moderna dosages authorized for 6 months – 5 years, depending on vaccination history and immune status	All Moderna doses in ages 6 months – 11 years are now 25 µcg	Reduces the number of COVID-19 vaccine products in use
Optional 2 <sup>nd</sup> bivalent dose for those ages 65 years and older	No additional dose recommendation <b>at this time</b>	Will monitor epidemiology and vaccine effectiveness to determine if additional doses are needed





# COVID-19 Vaccine Timing Guide

The COVID-19 Vaccine Timing 2023 – 2024 Routine Schedule Guide is updated!

Immunocompromised guidance coming soon!

## COVID-19 Vaccine Timing Guide 2023-24

### COVID-19 Vaccine Timing 2023-24 –Routine Schedule

Age*	Vaccine	If unvaccinated:	If had any prior doses, give 2023-24 doses:
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose → 3-8 weeks** → 2nd Dose → ≥8 weeks → 3rd Dose	If 1 prior dose, then: 3-8* weeks 1 ≥8 weeks 2 If ≥2 prior doses, then: ≥8 weeks 1
	Moderna–Pediatric*	1st Dose → 4-8 weeks** → 2nd Dose	If 1 prior dose, then: 1 month 1 If ≥2 prior doses then: 2 months 1
5–11 years	Moderna–Pediatric*	1 Dose	If 1 or more prior doses (of any of the 4 brands), then*: ≥2 months Updated 2023-24 Formulation Moderna/Pfizer
	Pfizer–Pediatric	1 Dose	
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose	2023-24 formulation coming soon!
	Moderna–Adol/Adult (Spikevax)	1 Dose	
	Novavax (2021)	1st Dose → 3-8 weeks** → 2nd Dose	

\* See [CDC recommendations](#) for children transitioning from a younger to older age group

† Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.

\*\* An 8-week interval may be preferable for some people, especially for males 12-39 years.

≠ All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).

^ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.

View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.



California Department of Public Health, Immunization Branch

IMM-1396 (9/14/23) Page 1 of 2



# COVID-19 Vaccine Product Guide - Updated

## COVID-19 Vaccine Product Guide



Check vaccine labels and [FDA materials](#) before use to avoid mix-ups.  
EUA fact sheets supersede info on vials and carton. Refer to [CDC Product Guide](#) for more information.

Pfizer		
Infant/Toddler 6 months–4 years	Pediatric 5–11 years	Comirnaty 12+ years
2023-24 Formula	2023-24 Formula	2023-24 Formula

Packaging	Yellow Cap	Blue Cap	Gray Cap
Doses Per Vial	3 doses	1 dose	1 dose
Carton Size	30 doses	10 doses	10 doses
NDC-Unit of Use (vial)	59267-4315-01	59267-4331-01	00069-2362-10
CVX Code	302	301	300
CPT Code	91318	91319	91320
Program Availability	VFC	VFC	VFC, BAP
Min. Standard Order*	30 doses	10 doses	10 doses

**Storage Limits Before Puncture:** Label vaccine with expiration and use-by dates.

ULT	Until expiration date at -90°C to -60°C (-130°F to -76°F)		
Thermal Shipper			
Freezer			
Refrigerator	Up to 10 weeks at 2° to 8°C (36°F to 46°F). Write the date on carton—not to exceed expiration.		
Expiration Date	Check the label or <a href="#">Pfizer product website</a> .		

Administration			
Diluent (supplied)	1.1 mL per vial	Do not dilute	Do not dilute
Dose Volume & Dose	0.3 mL 3 mcg dose	0.3 mL 10 mcg dose	0.3 mL 30 mcg dose
Refrigerator Thaw Time (Do not refreeze)	2 hours in carton (2° to 8°C/36°F to 46°F)		
Room Temp Thaw Time (Do not refreeze)	Vial: 30 minutes at up to 25°C (77°F)		
Total Time at Room Temp	Up to 12 hours (including thaw time) at 8°C to 25°C (46°F to 77°F)		

**Storage Limits After Puncture (Multi-dose vials):** Record puncture and use-by time on vial label.

Use-By Limit (Discard Time After 1st Puncture)	Discard 12 hours after dilution. Keep at 2°C to 25°C (35°F to 77°F)	N/A	N/A
--	---	-----	-----

\* Orders for privately purchased vaccines may have different order minimums.

California Department of Public Health, Immunization Branch

IMM-1399 (9/14/23) Page 1 of 3

## COVID-19 Vaccine Product Guide



Check vaccine labels and [FDA materials](#) before use to avoid mix-ups.  
EUA fact sheets supersede info on vials and carton. Refer to [CDC Product Guide](#) for more information.

Moderna		
Pediatric 6 months–11 years	Spikevax 12+ years	Spikevax 12+ years
2023-24 Product	2023-24 Product	2023-24 Product

Packaging	Dark Blue Cap	Dark Blue Cap	Syringe
Doses Per Vial	1 dose	1 dose	1 dose
Carton Size	10 doses	10 doses	10 doses
NDC-Unit of Use (vial)	80777-0287-07	80777-0102-04	80777-0102-01
CVX Code	311	312	312
CPT Code	91321	91322	91322
Program Availability	VFC	VFC, BAP	TBD
Min. Standard Order*	10 doses	10 doses	TBD

**Storage Limits Before Puncture:** Label vaccine with expiration and use-by dates.

ULT	
Thermal Shipper	
Freezer	Until expiration at -50°C to -15°C (-58°F to 5°F)
Refrigerator	Up to 30 days (not to exceed expiration date) at 2–8°C (36–46°F)
Expiration Date	Check <a href="#">Moderna product website</a> or QR code.

Administration			
Diluent (supplied)	Do not dilute		
Dose Volume & Dose	0.25 mL 25 mcg	0.5 mL 50mcg	0.5 mL 50mcg
Refrigerator Thaw Time (Do not refreeze)	45 minutes for single dose vial or 1 hour for syringe at 2°C to 8°C (36°F to 46°F). Let stand at room temp for 15 min before administering.		
Room Temp Thaw Time (Do not refreeze)	15 minutes for single dose vial or 45 minutes for syringe at 15° to 25°C (59° to 77°F)		
Total Time at Room Temp	Store up to 24 hours at 8°C to 25°C (46°F to 77°F)		

**Storage Limits After Puncture (Multi-dose vials):** Record use-by time on vial.

Use-By Limit (Discard Time After 1st Puncture)	N/A. Discard after single use.
--	--------------------------------

\* Orders for privately purchased vaccines may have different order minimums.

California Department of Public Health, Immunization Branch

IMM-1399 (9/14/23) Page 2 of 3

## COVID-19 Vaccine Product Guide



### Do Not Use Deauthorized Products:

Use only COVID-19 vaccine products updated for 2023-24.

Pfizer		
Infant/Toddler 6 months–4 years	Pediatric 5–11 years	Adol/Adult 12+ years
2021 Monovalent	2021 Monovalent	2021 Monovalent

Moderna				
Infant/Toddler 6 months–5 years	Infant/Toddler 6 months–5 years	6 months+	Pediatric 6–11 years	Adol/Adult 12+ years
2021 Monovalent	2021 Monovalent	2021 Monovalent	2021 Monovalent	2021 Monovalent

Janssen (J&J)
Adult 18+ years
2021 Monovalent

California Department of Public Health, Immunization Branch

IMM-1399 (9/14/23) Page 3 of 3



# Updated FDA Materials

- FDA Materials Updated from [Moderna](#) and [Pfizer](#):
  - Fact Sheet for Recipient and Caregivers
  - Fact Sheet for Healthcare Providers
  - Dear Healthcare Provider Letters
- CDC Material Updates in Progress
- CDPH Material Updates in Progress

## COVID-19, Flu and RSV

*FDA Resources for the Fall Respiratory Illness Season*

[Share](#) [Tweet](#) [LinkedIn](#) [Email](#) [Print](#)

You may be eligible for three vaccinations this fall – flu, COVID-19, and RSV (respiratory syncytial virus) – and wondering if you should get all three shots.

This is your guide to FDA-authorized and approved vaccines, tests and treatments for all three illnesses. Talk to a health care professional about what works best for you.

[Vaccines](#) | [Tests](#) | [Treatments](#)

VACCINES



COVID-19 Vaccines



Flu Vaccines


[FDA Resources for the Fall Respiratory Illness Season](#)

# Protect yourself from COVID-19, Flu and RSV

## CDC Respiratory Viruses page

[www.cdc.gov/respiratory-viruses/index.htm](https://www.cdc.gov/respiratory-viruses/index.htm)

- CDC recommends that everyone 6 months and older stay up to date on [COVID-19 vaccines](#) and receive a [seasonal flu vaccine](#).
- If you are 60 years and older, talk to your healthcare provider to see if RSV vaccination is right for you.
- CDC also recommends nirsevimab for all infants younger than 8 months who are born during or entering their first RSV season, as well as older babies 8 to 19 months old including AIAN children.





# Upcoming ACIP Meeting

CDC Advisory Committee on Immunization Practices (ACIP)

**Topic: Maternal RSV Vaccine**

**When: Friday, September 22, 2023**

Time: 7AM, PST

[Webcast Link to Join](#)

ACIP Meeting Agenda (Not Yet Posted)

# Storage and Handling: The Basics

Kate McHugh, CDPH





# Storage and Handling Basics

- COVID-19 Storage and Handling basics have not changed
- Please see, <https://eziz.org/vaccine-storage/>
- The webpage addresses:
  - Types and grades of refrigerators and freezers
  - Acceptable and unacceptable units
  - Digital Data Loggers & temperature monitoring
  - Vaccine management



# Commercialized **Spikevax** and **Moderna**

## **Presentations**

- Spikevax, Ages 12+
  - Single dose vials. 0.5 mL injection volume.
  - Prefilled Syringes, 0.5 mL injection volume.
- Moderna COVID-19 Vaccine, Ages 6 months - 11years
  - Single dose vials. 0.25 mL injection volume.

## **Minimum Order**

- 10 doses (Note: minimum order may be larger if purchasing through a wholesaler, e.g., + 60 doses)



# Commercialized **Moderna** (Spikevax)

- Storage (vials and prefilled syringes)
  - Long-term frozen storage or (9 to 12 months from date of manufacture)
  - Refrigerated storage for up to 30 days BUD
  - Normal room temperature for up to 24 hours
- Offering returns?
  - Yes



# Commercialized Novavax (coming soon?)

- Presentation
  - Ages 12+: 5 dose multi-dose vials. 0.5mL injection volume.
- Minimum Order
  - 10 doses, 2 vials
- Storage
  - Refrigerated expiry 9 months from date of manufacture
- Offering returns? Yes, up to 100% for opened and unopened vials



# Commercialized Pfizer and Comirnaty

- Presentations

- Pfizer COVID-19 Vaccine, 6 months – 4 years: Requires diluent (1.1 mL normal saline). 3 dose multi-dose vials. Yellow cap. 0.3 mL injection volume.
- Pfizer COVID-19 Vaccine, 5 years – 11 years: No diluent required. Single dose vials. Blue cap. 0.3 mL injection volume.
- Comirnaty, 12 years+: No diluent required. Single dose vials. Gray cap. 0.3 mL injection volume.

- Minimum Order

- 6 months – 4 years: 30 doses
- 5 years – 11 years: 10 doses (government supplied vaccine), 100 doses private purchase
- 12 years+: 10 doses (government supplied vaccine), 100 doses private purchase



# Commercialized **Pfizer** (Comirnaty)

- Storage
  - Long-term storage at ultracold temperatures, if vaccine was received at ultracold temperatures expiry (12 to 18 months from date of manufacture)
  - Short-term storage (10 weeks) at refrigerated temperatures (most wholesalers have said they plan to ship this way)
- Returns Offered?
  - Yes



# Links to the EUA Fact Sheets/Package Inserts

- Comirnaty, 12 years plus: [Comirnaty Prescribing Information Highlights](#)
- Spikevax, 12 years plus: [Spikevax Prescribing Information Highlights](#)
- Moderna, ages 6 month to 11 years: [Moderna COVID-19 Vaccine \(2023-2024\) Fact Sheet EUA Highlights](#)
- Pfizer, ages 6 months to 11 years: [Pfizer BioNTech EUA Fact Sheet Highlights](#)




# COVID-19 Vaccine Access





# COVID-19 Vaccine Access and Ordering



# COVID-19 Vaccine Transition to Commercialization

Vaccine availability for pediatric and adult populations to follow current models for non-COVID-19 vaccines upon COVID-19 Commercialization, post sunset of the USG COVID-19 Program.

## **Pediatric populations:**

- Vaccines will be made available through the Vaccines for Children (VFC) Program for eligible children under 19 years of age.
- Vaccines for privately insured patients will be purchased following similar established mechanisms in healthcare for non-COVID-19 vaccines.

### VFC Program Eligibility

Children 0 through 18 years of age who meet at least one of the criteria:

- Medicaid eligible
- Uninsured, or
- American Indian/Alaska Native, or
- Underinsured\*

\* Eligible to receive vaccine only through an enrolled Federally Qualified Health Center (FQHC), Rural Health Center (RHC) or a deputized provider under Delegation of Authority



# COVID-19 Vaccine Transition to Commercialization

## California's Vaccine For Children (VFC) Program

- 55% of CA children under 19 years of age (6.1M) are eligible to receive VFC supplied vaccines
- CA's program represents approximately 10% of the nation's provider participation-with over 3,500 active provider sites throughout the state
- Distributes over 9M doses of pediatric vaccines annually



The Vaccines for Children (VFC) program helps ensure that all children have a better chance of getting their recommended vaccines. VFC has helped prevent disease and save lives.



# COVID-19 Vaccines Addition to VFC Program

- COVID-19 vaccine is already a routinely recommended ACIP\* vaccine, and has been officially voted into the VFC\*\* Program.
- It is expected that ordering and availability for this vaccine, via routine VFC Program ordering processes, **will occur upon FDA approval of an updated monovalent COVID-19 vaccine, ACIP vote, CDC recommendation, AND available vaccine supply (Allocations).**

\*Advisory Committee on Immunization Practices-CDC

\*\*Vaccines for Children





# Pediatric COVID-19 Vaccine Ordering through VFC

- VFC COVID-19 Vaccine is anticipated to be available the week of 9/18/2023.
- VFC providers will order COVID-19 vaccine using the same order process they do for all other routine vaccines on the VFC order form of your [MyVFCVaccines](#) account.
- VFC Providers do NOT need to enroll in myCAvax.
- A new section for COVID-19 vaccines has been added to VFC's order Form.
- Products are grouped by Age to facilitate ordering.

COVID-19 Vaccines			
COVID-19 (6m - 4y)	<input type="text"/> VFC	1. --Choose vaccine-- # of Doses   Lot Number   Expiration (mm/dd/yyyy) <a href="#">Add More</a>	Pfizer 3 Dose Vial - 30 doses/10 Vials Per Box <input type="text"/>
COVID-19 (6m - 11y)	<input type="text"/> VFC	1. --Choose vaccine-- # of Doses   Lot Number   Expiration (mm/dd/yyyy) <a href="#">Add More</a>	Currently not available
COVID-19 (5y - 11y)	<input type="text"/> VFC	1. --Choose vaccine-- # of Doses   Lot Number   Expiration (mm/dd/yyyy) <a href="#">Add More</a>	Pfizer Single Dose Vials - 10 Per Box <input type="text"/>
COVID-19 (12y - 18y)	<input type="text"/> VFC	1. --Choose vaccine-- # of Doses   Lot Number   Expiration (mm/dd/yyyy) <a href="#">Add More</a>	--Choose vaccine-- <input type="text"/> <a href="#">Add More</a>



# Anticipated COVID-19 Vaccine Products in VFC

## Pediatric COVID-19 Vaccine Price List

**Note:** The table below reflects contracts for the 2023-2024 Pediatric COVID-19.

Vaccine	Brandname/ Tradename	NDC	Packaging	CDC Cost/ Dose	Private Sector Cost/ Dose	Contract End Date	Manufacturer
Covid-19 (Age 12 years and older)	Spikevax™	80777-0102-95	10 pack – 1 dose vial	\$85.91	\$128.00	6/6/2024	Moderna
Covid-19 (Age 6 months through 11 years)	COVID-19 Vaccine	80777-0287-92	10 pack- 1 dose vial	\$85.91	\$128.00	6/6/2024	Moderna
Covid-19 (Age 12 years and older)	Comirnaty®	00069-2362-10	10 pack- 1 dose vial	\$97.75	\$115.00	6/6/2024	Pfizer
Covid-19 (Age 5 years through 11 years)	COVID-19 Vaccine	59267-4331-02	10 pack- 1 dose vial	\$65.45	\$77.00	6/6/2024	Pfizer
Covid-19 (Age 6 months through 4 years)	COVID-19 Vaccine	59267-4315-02	10 pack- 3 dose vial	\$48.88	\$57.50	6/6/2024	Pfizer

\*Not yet available through VFC. ^ Products approved for emergency use (under EUA)



# All COVID-19 Products will be Offered to California VFC Providers for Ordering, as they become available & Supply Permits

Vaccine Group	Vaccine Name	Min Order Qty	NDC
COVID (6 months - 4 years)^	(Pfizer) 3 Dose Vial – 30 doses/10 Vials Per Box	30 doses	59267-4315-02
COVID (6 months - 11 years)^	(Moderna) Single Dose Vials - 10 Per Box*	10 doses	80777-0287-92
COVID (5 years - 11 years)^	(Pfizer) Single Dose Vials - 10 Per Box	10 doses	59267-4331-02
COVID (12 years - 18 years)	Comirnaty (Pfizer) Single Dose Vials - 10 Per Box	10 doses	00069-2362-10
		10 doses	80631-0105-02
	Novavax 5 Dose Vial – 10 doses/2 Vials Per Box*	10 doses	80777-0102-95
	Spikevax (Moderna) Single Dose Vials - 10 Per Box		

\*Not yet available through VFC. Moderna's pediatric presentation for children 6m-11y and Novavax's presentation for children will be available for ordering at a future date.

^ Products approved for emergency use (under EUA)






# COVID-19 Vaccine Transition to Commercialization

Vaccine availability for pediatric and adult populations to follow current models for non-COVID-19 vaccines upon COVID-19 Commercialization, post sunset of the USG COVID-19 Program.


## Adult populations:

- Anticipate **limited** vaccine supply will be made available through the **CA Bridge Access Program (BAP)** for uninsured/under insured adults.
- Bridge Access Program for Retail Pharmacies will also support adult uninsured/underinsured vaccination
- Vaccines for insured adults will be private supply, obtained via established processes, like non-COVID vaccines.



# Background on the Bridge Access Program (BAP)

On April 18, 2023, the U.S. Department of Health and Human Services (HHS) announced the [HHS Bridge Access Program](#) (BAP) for COVID-19 Vaccines and Treatments. BAP is a temporary measure created to prevent loss of access to free COVID-19 vaccines and treatment for uninsured and underinsured aged 19 years and older. The program will begin September 2023 and will end on December 31, 2024.

 Bridge Access Program	
Limited federal funds (Section 317) for adult populations to maintain access to COVID-19 vaccines through existing public health infrastructure	
<b>Adults 19 years and older:</b> <ul style="list-style-type: none"> <li>• Uninsured (no health insurance)</li> <li>• Underinsured (vaccines are not covered by insurance)</li> </ul>	

Topic	Bridge Access Program Quick Facts
<b>Storing Vaccine</b>	• Similar to previous products.
<b>Fees</b>	• Vaccine is provided free of charge. No administration fee for BAP
<b>Supply and Anticipated Products</b>	• Limited allocations of Pfizer, Moderna, and Novavax.
<b>Program Timeline</b>	• Bridge Access Program will end in December 2024
<b>Eligible Clinic Types</b>	• Public Health Clinics, FQHCs, RHC, Tribal Clinics, Indian Health, and other Designated facilities by Public Health Departments



# Anticipated COVID-19 Vaccine Products in CA's BAP

## Adult COVID-19 Vaccine Price List

**Note:** The table below reflects contracts for the 2023-2024 Adult COVID-19.

Vaccine	Brandname/ Tradename	NDC	Packaging	CDC Cost/ Dose	Private Sector Cost/ Dose	Contract End Date	Manufacturer	Contract Number
Covid-19 (Age 12 years and older)	Spikevax™	80777- 0102-95	10 pack- 1 dose vial	\$81.61	\$128.00	6/6/2024	Moderna	75D30123D16646
Covid-19 (Age 12 years and older)	Comirnaty®	00069- 2362-10	10 pack- 1 dose vial	\$85.10	\$115.00	6/6/2024	Pfizer	75D30123D16650

**NOTE:** Novavax vaccine is not yet available through BAP and will be available for ordering at a future date.

Federal contracts have been modified to allow a sooner delivery of the 2023-2024 COVID-19 vaccines within public health infrastructure for children and adults.

Updated CDC Vaccine contract information has been posted, and for adult populations, current products are included in the list.

# COVID-19 Vaccine Access: Pharmacy

Edward Salaguinto, PharmD, RPh, CDPH





# Where Will Vaccines Be Available for Pharmacies Through the Bridge Access Program?

- Select pharmacies will ensure access to no cost COVID-19 vaccines using their extensive footprints and community partnerships.
- Vaccines will be donated by manufacturers to pharmacies (via product reimbursement), and administration costs will be covered by CDC.






# Bridge Access Program for Retail Pharmacies

- CVS plans to administer doses within both their storefronts and Minute clinics.
- Walgreens plans to administer doses in both their storefronts and at off-site events targeting areas of low access & low uptake.
- eTrueNorth is a pharmacy aggregator that subcontracts with smaller pharmacies – Intended to reach lower-access areas without other coverage within the Bridge Access Program.
- Additional subcontract negotiations between eTrueNorth and possible additional participating pharmacies are ongoing.
- Pharmacies are required to identify if they are a BAP participant on [vaccines.gov](https://www.vaccines.gov).
  - As of this morning, [vaccines.gov](https://www.vaccines.gov) was being updated.



# Pharmacy Commercial Product Arriving

- Pharmacies are expected to have commercial COVID-19 vaccine soon.
  - Expected to be roll into pharmacies as early as yesterday and through the weekend.
- Some pharmacies have appointments available as early as Monday.
- BAP Pharmacies will be able to provide COVID-19 vaccine to insured patients and uninsured patients with the same supply.
  - Some BAP systems are in place, however, may not be active yet. Patient must check with pharmacy if they are taking BAP patients.
- As of this morning, vaccines.gov was not yet updated.





## CDPH Slide Icons



Event/Calendar



Checklist: CA COVID-19 Vaccination Program Close-out



Wastage



Hot Topic: Updated COVID-19 Monovalent Vaccine



COVID-19 Vaccine Access



Bridge Access Program (BAP)



Alert/New/Updated



Reporting

# Vaccine Management

Josh Pocus, My Turn, and Maria Volk, myCAvax

# What's Next in My Turn? – Release 43



New updates for My Turn Public and Clinic will launch on  
**Wednesday, September 20, 2023!**



## Release Highlights



### My Turn Public

When scheduling vaccine appointments, patients **will be able to view:**

- ✓ A filter on the clinics that serve either insured or uninsured / under-insured patients based on the health insurance question
- ✓ New 'Serves insured' and 'Serves uninsured' tags on the 'Select a Location' and 'Walk-in' pages
- ✓ The clinic phone number in the 'Clinic Details' section
- ✓ An updated description on the clinic card that says "Please contact the clinic to confirm the patient's insurance is accepted"

When scheduling vaccine appointments, patients **will no longer be able to view:**

- ✓ The 'Yes, but cannot provide information' option on the health insurance question

## Release Highlights



### My Turn Clinic

Clinic Managers and Vaccine Administrators **will be able to:**

- ✓ Add multiple funding sources to a single vaccine inventory
- ✓ Select / update funding source on the Walk-in, IIS Edit, Inline / Bulk Upload, and Vaccine Administration flows
- ✓ Select vaccine supply for publicly or privately funded vaccines when creating a clinic
- ✓ View / download new reports that include vaccine funding source and patient insurance information for billing purposes
- ✓ Add privately purchased vaccines to the clinic inventory

# What to Expect: My Turn and BAP

CDPH anticipates the deauthorization of U.S. Government COVID-19 vaccine.



CMs will need to:



Add or update a required clinic phone number and clinic availability



Add new vaccine supply\* and inventory (if offered); update new inventory with available funding sources



Remove deauthorized vaccine supply



Update or cancel future clinic appointments; deactivate clinics that have no supply or will not offer future supply

**\*NOTE:** Vaccine supply is now distinguished by insurance status and will impact public clinic tags and scheduling.

# What's Next in myCAvax? – Release 43



New updates for Providers will launch on  
**Friday, September 22, 2023!**



## Providers

### Release Highlights



Providers will:

#### Shipment Incident

- ✓ See updated fields on the 'New Shipment Incident' pop-up window

#### Provider Community Site

- ✓ See an updated landing page displaying program tiles based on the Provider's Program enrollment permissions
- ✓ See the 'Program Selected' dropdown on multiple pages based on the Provider's Program enrollment permissions
- ✓ See orders on the 'Vaccine Orders' page based on the program selected from the 'Program Selected' dropdown
- ✓ See the COVID-19 or SGF 'Shipment Incidents' page based on the program selected from the 'Program Selected' dropdown
- ✓ See the COVID-19 or SGF 'Dashboard' page based on the program selected from the 'Program Selected' dropdown
- ✓ No longer see the 'Open Transfer Orders' pop-up window on the landing page

### Vaccine Ordering – Provider

- ✓ See the COVID-19 or SGF 'Vaccine Order Request' page based on the program selected from the 'Program Selected' dropdown
- ✓ Be able to place vaccine order requests for SGF flu vaccine on the 'State General Fund - Vaccine Order Request' page
- ✓ Receive email notifications when their vaccine order request has been rejected or progressed to 'Fulfillment Pending'
- ✓ Receive a reminder email for an expiring COVID-19 or Outbreak draft order four days after the order creation date
- ✓ Have their draft orders deleted seven days after the order creation date; they will also receive a confirmation email for the same
- ✓ Be directed to the appropriate 'Vaccine Order Request' page when they click the 'Submit Order' button on a draft order

### Location Account

- ✓ Have their location account's sub-status updated to 'On-Hold' and the 'Reason for On-Hold' field updated with the 'Provider Account Changes' value when the shipping address fields are updated

# U.S. Government COVID-19 Program Disenrollment



For Providers not participating in the Bridge Access Program, CDPH has updated your COVID-19 program activity status to inactive as the U.S. Government COVID-19 program has ended. You can no longer place orders or manage COVID-19 vaccine inventory for this program.


Providers selected to participate in the Bridge Access Program will receive an additional email with enrollment instructions.

Thank you for your continued efforts to protect Californians against COVID-19.




# Beginning BAP Enrollment for Selected Providers

If you are selected to participate in the Bridge Access Program, upon logging in to myCAvax, eligible locations will pop up on the home page after completing the required training.





# Completing BAP Enrollment for Selected Providers


**Program Location**  
 Water Cooler Healthcare - COVID-19

**Vaccination Provider Profile**  
 Provide the following patient vaccination estimates for your location.  
  
 Estimated number of all patients 19+ years old who will receive immunizations at your location during the upcoming 12 month period, by category (both BAP eligible and privately insured patients)

- Number of Uninsured / Under-insured adults 19-64 years of age annually
- Number of Uninsured / Under-insured adults 65 years of age and older annually
- Privately insured (including Medi-Cal and Medicare) 19-64 years of age annually
- Privately insured (including Medi-Cal and Medicare) 65 years of age and older annually


**Provider Agreement**  
 A signed copy of the [provider agreement](#) is needed from the provider of record.

Or drop files

▼

File Name

▼


 Program Location Provider Agreement - Water Cooler Healthcare - COVID-19
 

▼

Your Provider of Record will need to sign the Bridge Access Program (BAP) Provider Participation Agreement, which is available on [EZIZ](#).



# Bridge Access Program Allocation and Ordering Update




CDPH is awaiting additional Bridge Access Program vaccine allocation. We anticipate BAP vaccine ordering will be available to Providers shortly. Expect ordering updates from CDPH via email.

## To prepare to order, Providers must:

- ✓ Complete required training\*
- ✓ Enroll your location in BAP in myCAvax
- ✓ Upload your signed Provider Agreement in myCAvax

**\*NOTE:** Required CDC product training has not been released. For now, review vaccine fact sheets.

# Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
	This is to label slides that include important system reminders.
	This is to label slides that include tips and best practices to improve your system experience.

# My Turn – Known Issues – *Updated 9/8*



## Known Issues

### **‘Account’ and ‘Lot Number’ Dropdowns Blank when Creating Vaccine Inventory**

- ✓ We are investigating an access issue for some Clinic Managers and Vaccine Administrators, even if the contact is set up correctly.
- ✓ If you are affected, you will see missing data such as blank ‘Account’ and ‘Lot Number’ dropdowns when creating vaccine inventory.



## Workaround / Next Steps

- ✓ Estimated Fix: TBD
- ✓ Workaround: If you experience this issue, please reach out to the Provider Call Center.

# myCAvax – Known Issues – *Updated 9/11*



## Known Issues

### **COVID-19 Enrollment Only Allowing 25 Characters for Location Name**

- ✓ We will be correcting an issue in which the COVID-19 'Add Location' process is only allowing up to 25 characters to be entered for the location name. It should allow up to 35 characters. If this occurs to you, please shorten the name for the time being.

### **Wrong Primary Vaccine Coordinator Listed on the Community's 'Locations' tab**

- ✓ We are working to correct an issue in which old Primary Vaccine Coordinators are displayed on the 'Locations' tab under some circumstances.



## Workaround / Next Steps

- ✓ Estimated Fix: 9/22

- ✓ Estimated Fix: 9/22

# Pharmacy COVID-19 Therapeutics Updates

Edward Salaguinto, PharmD, RPh, CDPH

# AB-1341 Update: Passed

### On the governor's desk awaiting signature

- Urgency clause – bill would go into effect immediately after signed.
- Governor must sign or veto by 10/14/2023

## Highlights of the bill

- Pharmacist may furnish COVID-19 oral therapeutics following a positive test for SARS-CoV-2
  - NOTE: positive test is not required for other prescribers.
- Pharmacist shall utilize relevant and appropriate evidence-based clinical guidelines published by the FDA in providing these patient care services.
  - Note: No off-label prescribing allowed for pharmacists.
- Pharmacist must notify the patient's primary care provider.
  - If patient does not have a PCP pharmacist must make a patient record and retain.
- "COVID-19 oral therapeutics" means drugs that are approved or authorized by the FDA for the treatment of COVID-19 and administered orally. This covers FDA approved & EUA oral antivirals.
  - NOTE: Lagevrio EUA states LAGEVRIO may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which LAGEVRIO belongs (i.e., antiinfectives). Pharmacists are not authorized prescribers of Lagevrio.



# Paxlovid Commercialization Update

- All of the EUA product that Pfizer has produced has been purchased by the federal government and Pfizer has fulfilled and delivered all the government's orders.
- According to Pfizer, it's their understanding that the federal government will not purchase any of the FDA approved Paxlovid
- Expected that all FDA approved Paxlovid will be only available commercially
- The earliest Paxlovid will be available commercially will be prior to the end of this year. The latest Paxlovid will be available commercially will be mid-summer 2024.
- BAP for therapeutics?
  - For Paxlovid, Pfizer states that once fed supply is exhausted, patients must enroll into Pfizer's Patient Assistance Program for Paxlovid at no cost for the uninsured.
  - For Lagevrio, more information forthcoming from Merck.



# EUA & FDA Approved NDCs

## PAXLOVID™ (nirmatrelvir/ritonavir) product information<sup>2,4</sup>

### FDA-approved commercial supply

How supplied	NDC number (carton)*	NDC number (blister)*
Standard dose (300 mg nirmatrelvir/ 100 mg ritonavir) <sup>†</sup>	0069-5321-30	0069-5321-03
Reduced dose <sup>‡</sup> (150 mg nirmatrelvir/ 100 mg ritonavir)	0069-5317-20	0069-5317-02

### EUA government-purchased supply

How supplied	NDC number (carton)*	NDC number (blister)*
Standard dose (300 mg nirmatrelvir/ 100 mg ritonavir) <sup>†</sup>	0069-1085-30 or 0069-0345-30	0069-1085-06 or 0069-0345-06
Reduced dose <sup>‡</sup> (150 mg nirmatrelvir/ 100 mg ritonavir)	0069-1101-20	0069-1101-04

\*Different NDC numbers are indicative of the different ritonavir manufacturers. Each ritonavir manufacturer places its own debossing code on the ritonavir tablet. There are no other differences in the ritonavir tablets.

<sup>†</sup>No dosage adjustment is needed in patients with mild renal impairment (eGFR  $\geq 60$  to  $< 90$  mL/min).

<sup>‡</sup>For patients with moderate renal impairment (eGFR  $\geq 30$  to  $< 60$  mL/min).

**PAXLOVID is not recommended in patients with severe renal impairment (eGFR  $< 30$  mL/min) or severe hepatic impairment (Child-Pugh Class C).**

eGFR = estimated glomerular filtration rate; EUA = emergency use authorization; NDC = National Drug Code.

# Shelf-Life Extensions for COVID-19 Oral Antiviral Therapeutics

- The Administration for Strategic Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) announced the authorization of a shelf-life extension to 24 months for Paxlovid, and 30-36 months for Lagevrio.
- Be sure to check all inventory for the extended expiration dates.
- Do not destroy or dispose of any Paxlovid or Lagevrio that has not expired. It is the property of the federal government.

[Shelf-Life Extension for Lagevrio \(hhs.gov\)](#)

[Shelf-Life Extension for Specific Lots of Paxlovid | HHS/ASPR](#)

# Resources

Leslie Amani, CDPH

# COVID-19 Vaccine Support


## Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: [myCAvax.hd@cdph.ca.gov](mailto:myCAvax.hd@cdph.ca.gov)
- For My Turn Clinic Help Desk inquiries: [MyTurn.Clinic.HD@cdph.ca.gov](mailto:MyTurn.Clinic.HD@cdph.ca.gov)
- For all other inquiries: [providercallcenter@cdph.ca.gov](mailto:providercallcenter@cdph.ca.gov)
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

## myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.  Need help? View our jobs aids in the Knowledge Center, or contact us.



# Commercialization at a Glance: Provider Transition Guide

## Commercialization at a Glance: Provider Transition Guide



### California COVID-19 Vaccination Program

Commercialization is the transition of COVID-19 medical countermeasures—vaccines, treatments, and test kits—previously purchased by the U.S. Government (USG) to established pathways of procurement, distribution, and payment by both public and private payers. This guide summarizes the [HHS Commercialization Transition Guide](#), [HHS Bridge Access Program Fact Sheet](#), and CDPH guidance as the USG prepares to stop distributing COVID-19 vaccines and vaccines transition to the commercial market. Updated topics highlighted below. Sections include:

- Fall Transition Timeline
- Sunsetting of the Federal COVID-19 Vaccination Program
- Commercialization of COVID-19 Vaccines
- Anticipated Vaccination Schedule for the Fall

Topic	Guidance	Effective Date
Section 1	Fall Transition Timeline	
	<div><div>Week of July 31, 2023</div><div>August 3-Early September</div><div>TBD (expected early to mid-September)</div><div>TBD (ACIP Recommendation + 2 weeks=Late September/Early October)</div></div> <div><ul style="list-style-type: none"><li>• CDC set vaccine thresholds to -0- in anticipation of decreased vaccine demand</li><li>• Providers were asked to order a 2-month vaccine supply to last until new products are approved by FDA</li><li>• Vaccine doses can still be ordered by States, but the processes, timing, and cadence for ordering processing will change. Based on doses ordered, we ask CDC for allocations, wait 1-3 days for doses, then transmit orders to CDC.</li><li>• Providers may still submit additional Small Orders if needed. But these are NOT sent to CDC. These are fulfilled locally/TPR.</li><li>• Larger orders are now only available to LHDs/MCEs.</li><li>• ALL healthcare providers are advised to begin planning, prebooking or procuring COVID-19 vaccine doses for privately insured individuals.</li><li>• States begin to plan closeout of USG COVID-19 Program, and implementation of much smaller Bridge Access Program, and addition of COVID-19 vaccines to VFC Programs.</li><li>• FDA decisions and amendments to Emergency Use Authorizations (EUAs) / Biologics License Applications (BLAs) Approve new products, and de-authorized current products.</li><li>• Concurrently, USG WILL discontinue distribution of current COVID-19 vaccine composition.</li><li>• Advisory Committee on Immunization Practices (ACIP) discussion on COVID-19 epidemiology and vaccine effectiveness and CDC recommendation.</li><li>• CDPH and LHDs work on BAP provider enrollment, and prepare for COVID-19 ordering for BAP Provider and VFC Providers.</li><li>• Fall vaccine availability for administration begins across all eligible age groups, with corresponding vaccine supply based on insurance coverage, and eligibility (for providers participating in VFC or CA's Bridge Access Program)</li><li>• Providers will dispose of any remaining supply of de-authorized COVID-19 vaccines</li></ul></div>	

California Department of Public Health, IZ Branch

1

IMM-1467 (9/8/23)

CDPH has created a multiple-page “Commercialization Provider Transition Guide”.

The current information, and other resources, can be found on EZIZ.org using this link:

[Commercialization at a Glance: Provider Transition Guide](#)

Updated: 9.8.23

# COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated 9/14/2023
- Currently in its 132nd iteration!



**Q: Following FDA authorization and CDC recommendations for the updated 2023-2024 COVID-19 vaccines, are bivalent mRNA COVID-19 vaccines still authorized for use?**

A: No. Bivalent mRNA COVID-19 vaccines are no longer authorized for use. To prevent [vaccine administration errors](#), Providers should report and dispose of COVID-19 vaccines:

- Remove all bivalent mRNA COVID-19 vaccines from storage units regardless of expiration dates.
- Dispose of all bivalent mRNA COVID-19 vaccine vials in pharmaceutical waste containers or comingled pharmaceutical/sharps waste containers in accordance with local regulations and practice protocols for the disposal of regulated medical waste.
- Inactive providers can now report waste in myCAVax. The waste reporting deadline is Saturday, September 30, 2023, by 11:59PM. Report vaccine products as “Waste” in myCAVax and use “Other” to add comment “deauthorized.”

COVID-19 Vaccine FAQs v.132\_9.14.23 1

## COVID-19 Vaccine FAQs

For Providers administering COVID-19 vaccine.  
Providers may also visit [EZIZ.org COVID-19 Webpage](#) and [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

### Contents

New and Updated FAQs .....	2
Vaccine Program Management.....	3
Vaccine Administration .....	4
Vaccine Storage & Handling .....	5
Reporting.....	5
Communication Resources.....	6





# EZIZ COVID-19 Resources Page

Accessible from BAP Menu and EZIZ Home Page!

## Vaccine Information

- COVID-19 Vaccine Access & Ordering infographic
- COVID-19 Product & Timing Guides (**Updates coming soon!**)
- EUA Fact Sheets, package inserts, FDA pages, manufacturer websites
- General resources including guidance about fall products from FDA & CDC

## Vaccine Administration

## Communicating with Patients

- Resources for Patients
- Vaccine Confidence



### COVID-19 Vaccine Resources

This landing page provides vaccine-specific resources to support all programs that supply COVID-19 vaccines. Relevant links are still being moved from the former EZIZ/COVID page. Please check back!

#### Vaccine Information

There is not a COVID-19 Vaccine Information Statement. Federal law allows up to 6 months for a new VIS to be used. EUA Fact Sheets for Recipients should be provided to patients at the time of vaccination for approved vaccine products. (See CDC guidance.)

- COVID-19 Vaccine Access & Ordering (Infographic)
- COVID-19 Vaccine Product Guide
- COVID-19 Vaccine Timing Guide | Spanish

#### Pfizer-BioNTech (2023-24 COVID-19 Vaccine, mRNA)

- Approval of Comirnaty for 12Y+: [Provider Letter](#) | [Package Insert](#) | [COMIRNATY \(FDA\)](#)
- Authorization under EUA for 6M-11Y: [Provider Letter](#) | [Fact Sheet for HCPs](#) | [Fact Sheet for Recipients & Caregivers](#) | [Pfizer-BioNTech COVID-19 Vaccine \(FDA\)](#)
- Websites: [Manufacturer](#) | [CDC Resources](#)

#### Moderna (2023-24 COVID-19 Vaccine, mRNA)

- Approval of Spikevax for 12Y+: [Provider Letter](#) | [Package Insert](#) | [FDA page](#)
- Authorization under EUA for 6M-11Y: [Provider Letter](#) | [Fact Sheet for HCPs](#) | [Fact Sheet for Recipients & Caregivers](#) | [Moderna COVID-19 Vaccine \(FDA\)](#)
- Websites: [Manufacturer](#) | [CDC Resources](#)

#### Novavax (2021 COVID-19 Vaccine, Adjuvanted)

- Authorization under EUA for 12Y+: [Fact Sheet for HCPs](#) | [Fact Sheet for Recipients & Caregivers](#) | [Novavax COVID-19 Vaccine \(FDA\)](#)
- Websites: [Manufacturer](#) | [CDC Resources](#)

#### General Resources

- CDC Recommends Updated COVID-19 Vaccine for Fall/Winter Virus Season (CDC)
- Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants (FDA)
- Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023 (FDA)
- Resources for the Fall Respiratory Illness Season (COVID-19, Flu and RSV) (FDA)

#### Vaccine Administration

- [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) (CDC)
- [ACIP Recommended Immunization Schedules: Child and Adolescent](#) | [Adult](#) (CDC)
- [Coadministration of COVID-19 Vaccines](#) (CDC) | [Coadministration Tips](#) (graphic)
- [Reporting Adverse Events to VAERS](#)
- [Reporting Race & Ethnicity](#)
- [Tips to Ease Anxiety During Vaccination](#)
- [Vaccine Administration Checklist](#) (to be updated after FDA authorizations)
- [More Job Aids](#)

#### Communicating with Patients

- [COVID-19 Vaccine Resources for Patients](#)
- [COVID-19 Vaccine Confidence](#)





# EZIZ BAP Landing Page!

- 1 From EZIZ Home Page:
- 2 BAP Vaccine Updates
- 3 Program Resources
  - BAP at a Glance
  - FAQs
  - BAP Talking Points
  - Infographic: Where can I get vaccines?
- 4 Program Information Menu
  - [BAP Resources](#)
  - [COVID-19 Vaccine Resources](#)
  - [Implementation Timeline](#)
- 5 Provider Call Center



**California's Vaccine Programs**


<b>VFC</b> California Vaccines for Children Program	<b>VFA</b> California Vaccines for Adults Program	<b>BAP</b> California Bridge Access Program	<b>317</b> Local Health Departments
--	--	--	--

Ordering & Vaccine Management	Storage Requirements
<ul style="list-style-type: none"><li>MyVFCvaccines (for VFC and VFA)</li><li>MyCAvax (for BAP and 317)</li></ul>	<ul style="list-style-type: none"><li>Vaccine Storage Units</li><li>Digital Data Loggers</li></ul>

**Alerts!**

**2023 COVID-19 Vaccine**

- CDC Recommends Updated 2023-2024 COVID-19 Vaccines for Everyone 6 Months and Older (9/13)
- New COVID-19 Vaccine Resources page



**California Bridge Access Program**

No-cost COVID-19 vaccines for uninsured & underinsured adults

**Alerts:**

CDPH is working closely with partner organizations to prepare all necessary resources for the Bridge Access Program. Please continue to check this webpage for updates.

**Vaccine Updates**

- CDC Recommends Updated 2023-2024 COVID-19 Vaccines for Everyone 6 Months and Older **NEW** September 13
- FDA Authorizes Updated COVID-19 mRNA Vaccines September 12
- September and October COVID-19 Vaccine Expiration Dates September 7
- COVID-19 Vaccine Commercialization FAQs Updated 9/1
- Commercialization at a Glance: Provider Transition Guide Updated 9/8
- Check back for updates about BAP Vaccine ordering opening date!

**Program Overview**

On April 18, 2023, the U.S. Department of Health and Human Services (HHS) announced the HHS Bridge Access Program (BAP) for COVID-19 Vaccines and Treatments. The BAP is a temporary measure connected to the commercialization of COVID-19 vaccines and treatment. It was created to prevent loss of access to free COVID-19 vaccines and treatment for uninsured and underinsured aged 19 years and older. The program will begin September 2023 and will end on December 31, 2024. More detailed information can be found at the CDC's Bridge Access Program Page, and in the CDPH BAP Requirements at a Glance.

The State program will utilize existing public health infrastructure, HRSA-supported health centers, and participating pharmacies via two major components:

- Provide support for the existing public section vaccine safety net, implemented and maintained by state immunization programs and HRSA-supported health centers.
- Create a funded partnership with pharmacy chains that will enable them to continue offering free COVID-19 vaccinations and treatments. This is a separate component under federal contract with key pharmacy chains. Participating chains will be able to provide COVID-19 vaccines to uninsured adult populations as well. All information on this landing page addresses the public health component.

**Program Resources**

- Requirements at a Glance (includes guidance and job aids)
- COVID-19 Commercialization FAQs on BAP (updated weekly)
- Talking Points for BAP COVID-19 Vaccines and Treatment (NCIRD)
- Infographic - Where Can Someone Get Vaccine? (CDC)
- California BAP Timeline

**Program Information**

- BAP Overview
- BAP Resources
- COVID-19 Vaccine Resources
- Implementation Timeline
- CAIR Requirement
- Communications & Webinars

**Provider Call Center**

- Phone: (833) 502-1245
- Hours: Mon-Fri, 8AM-5PM
- Email: [Program Info](#)
- [myCAvax Technical Support](#)
- [MyTurn Technical Support](#)

[Manufacturer Contacts](#)

[EDIT \[vfa-317/bap/support\]](#)






# CA Bridge Access Program Provider Operations Manual


This manual provides step-by-step instructions and links to available resources.

## Audience:

- Existing COVID-19 vaccine providers new to BAP
- New BAP organizations & locations




**Startup Worksheet**  
(for new organizations & locations)





# CA Bridge Access Program: At a Glance

## Requirements at a Glance



This document will be continuously updated as information and new resources become available.

COVID-19 vaccine product and CDC's Vaccine Product Training will be posted after FDA authorization/CDC recommendation.

**Who's Eligible:** Providers serving uninsured/underinsured adults through public health departments, Federally Qualified Health Centers (FQHCs)/Rural Health Centers, tribal clinics, Indian Health Services sites, and additional providers deemed eligible by LHDs

**What You Need to Know:** The California Bridge Access Program provides no-cost COVID-19 vaccines to uninsured/underinsured adults (19 years and older) served by enrolled and approved providers. Vaccine supply is limited. Insured patients—including patients covered by Medicare and Medi-Cal—are NOT eligible. Providers must conduct eligibility screening and proper documentation with each administration to ensure vaccines go to eligible adults. Limited supplies of the updated monovalent (XBB subvariant) COVID-19 vaccine will be provided through two components of the state program:

**Program Components:**

- Public Health Component:** Coordinated by State Immunization Programs, in collaboration with existing public health infrastructure. CDPH will allocate to each LHD doses of COVID-19 vaccines based on federally provided vaccine purchase funding limits. Doses allocated will support vaccination of uninsured and under-insured populations at local health departments, FQHCs/RHCs, Tribal and IHS clinics, and other safety net providers selected by LHDs for enrollment in the CA Bridge Access Program.
- Pharmacy component:** Independently coordinated by CDC with 3 contracted pharmacy chains/organizations: CVS, Walgreens, and E-True North (for independent and other pharmacies), who will receive supplies replenished by the COVID-19 Vaccine manufacturers directly; the specific sites receiving vaccine are not yet determined, and enrollment information is still forthcoming. All information in this document addresses the public health component.

Topic	Requirements & Guidance	Resource Links
★	<b>What's new for existing COVID-19 providers?</b> California's BAP Provider Participation Agreement replaces the federal COVID-19 Provider Agreement. While most requirements remain the same, look for orange stars identifying new requirements and job aids to assist you.	
Primary Documents	<ul style="list-style-type: none"> <li><a href="#">BAP Provider Participation Agreement</a></li> <li><a href="#">BAP Provider Operations Manual</a> (and <a href="#">Startup Worksheet</a> for new providers)</li> <li><a href="#">COVID-19 Vaccine Commercialization FAQs</a></li> </ul>	

Overview document links requirements and guidance to new resources!

Topics include:

- Provider Participation Agreement
- Required Vaccine Product Training
- Storage and Handling
- Reporting
- Vaccine Product Information
- Fact Sheets
- Much more to explore!

## BAP Requirements at a Glance



# New EZIZ BAP Resources Page!

## Eligibility Screening & Documentation

### Eligibility Based on Insurance Status

#### Bridge Access Program

A limited supply of COVID-19 vaccine will be made available through the Bridge Access Program for uninsured and underinsured adults (19 years and older) to prevent loss of access when vaccines transition to the commercial market. Insured patients—including patients covered by Medicare and Medi-Cal—are **NOT** eligible for the COVID-19 vaccines provided through this program. This temporary program will sunset at the end of 2024.

☒ **Eligible for COVID-19 Vaccine through BAP (317 Funds)**

Patient health insurance status:

- **Uninsured/No Insurance** (includes those who receive primary care through county safety net programs; these are NOT considered health insurance)
- **Underinsured** (has health insurance, but the insurance does not include any vaccines; insurance covers only selected vaccines; insurance does not provide first-dollar coverage for vaccines.)
- **Insurance NOT through Medi-Cal or Medicare** (only eligible for COVID-19 vaccines if **NOT** covered by patient's private insurance plan)<sup>1</sup>

☒ **Not Eligible for COVID-19 Vaccine through BAP (317 Funds)**

Patient health insurance status:

- **Medi-Cal Fee-For-Service/Medi-Cal Managed Care** ([bit.ly/CAhealthplans](http://bit.ly/CAhealthplans))
- **Medicare Part B** (medical benefit) **AND** Part D (prescription drug benefit)
- **Medicare Part B Alone**
- **Medicare Part D Alone**
- **Insurance NOT through Medi-Cal or Medicare**<sup>1</sup>

1. Fully insured adults whose insurance covers the cost of the vaccine(s) are NOT eligible for COVID-19 vaccine—even if the insurance includes a high deductible or co-pay, the plan's deductible has not been met, or the insurance has cost sharing.

California Department of Public Health, Immunization Branch IMM-1473 (9/23)

### 317 (VFA & BAP) Eligibility Screening & Documentation Requirements

#### 1. Screen for Eligibility

Eligibility screening must be conducted prior to the administration of any 317-funded vaccine (e.g., Vaccines for Adults and Bridge Access Programs). Eligibility is self-reported by the patient and verification of eligibility can be obtained verbally from the patient.

☒ **Eligible for VFA and/or BAP (COVID) vaccines if at least 19 years of age and**

1. Has no insurance, or
2. Is underinsured (public or private health insurance does not cover all vaccines or covers vaccines with a fixed dollar limit which has been reached)

☒ **Eligible for certain VFA vaccines if at least 19 years of age and**

3. Has Medicare **Part B**, but **NOT** Part D, patient is eligible for:
  - Hep A
  - Hep B (if considered low risk for Hep B)
  - HPV, MMR, Varicella, and Zoster
  - Td (if no wound exposure) and Tdap
4. Has Medicare **Part D**, but **NOT** Part B, patient is eligible for:
  - Hep B, PCV20

#### 2. Document Patient's Eligibility

There are three important elements to include when you document a patient's eligibility:

1. Date of screening
2. If patient is eligible for the Vaccines for Adults (VFA) and/or Bridge Access Program (BAP)
3. If patient is eligible **AND** at least 19 years of age, document which of the criterion above is met

#### 3. Use a Compliant Record Keeping System

- **CAIR and Electronic Health/Medical Record (EHR/EMR)**  
Note: if your practice's EMR/EHR does not capture all the necessary screening elements, they may be documented in the system's notes section.
- **CAIR and 317 Eligibility Screening Form (IMM-1226)**

Make sure to maintain patient eligibility screening records for a minimum of 3 years. [Refer to the 317 CAIR Documentation Requirement.](#)

#### 4. Communicate the Patient's Eligibility

All staff should be knowledgeable of eligibility. Ensure practice protocols are in place so vaccinators know when to use 317-funded versus private vaccines.

California Department of Public Health, Immunization Branch IMM-1476 (8/31/23)

### 317 (VFA & BAP) Eligibility Screening Record for Adult Patients

At each immunization visit, determine if patients are eligible for COVID-19 vaccines (if participating in the Bridge Access Program) and/or other routinely recommended vaccines through 317 funds (e.g., VFA).

#### Patient Information

Patient Name (Last, First, MI): \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Provider Name: \_\_\_\_\_

#### Eligibility Criteria for 317-Funded Vaccines (e.g., VFA and BAP)

☒ **Eligible for VFA and/or BAP (COVID) vaccines if at least 19 years of age and**

1. Has no insurance, or
2. Is underinsured (public or private health insurance does not cover all vaccines or covers vaccines with a fixed dollar limit which has been reached)

☒ **Eligible for certain VFA vaccines if at least 19 years of age and**

3. Has Medicare **Part B**, but **NOT** Part D, patient is eligible for:
  - Hep A
  - Hep B (if considered low risk for Hep B)
  - HPV, MMR, Varicella, and Zoster
  - Td (if no wound exposure) and Tdap
4. Has Medicare **Part D**, but **NOT** Part B, patient is eligible for:
  - Hep B, PCV20

#### Document Patient's Eligibility

Write the screening date and check appropriate status. (Note: verification of responses is not required. Keep this record for at least 3 years and make it available to state or federal officials upon request.)

Screening Date	✓ Eligible for VFA and BAP (COVID) (No insurance)	✓ Eligible for VFA and BAP (COVID) (Underinsured)	✓ Eligible for some VFA vaccines (Medicare Part B or Part D only)	✗ Not Eligible for BAP (COVID) (Medicare Part B or Part D only)	✗ Not Eligible for VFA or BAP (COVID) (Both Medicare Part B & D or insurance pays for vaccines <sup>1</sup> )
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/> Part B <input type="checkbox"/> Part D	<input type="checkbox"/>

<sup>1</sup> Note: adults enrolled in Medi-Cal or Medi-Cal Managed Care are considered insured.  
California Department of Public Health, Immunization Branch IMM-1226 (8/28/23)

### BAP Resources

#### Program Participation

- [Requirements at a Glance](#)
- [Provider Operations Manual \(POM\)](#)
- [Required Vaccine Product Training](#)

#### Eligibility Screening & Documentation

- [BAP Eligibility Based on Insurance Status](#)
- [317 \(VFA & BAP\) Eligibility Screening and Documentation Requirements](#)
- [317 \(VFA & BAP\) Eligibility Screening Record | Spanish](#)
- [VFA & BAP Patient Vaccine Poster | Spanish](#)
- [Vaccine Program Eligibility Guidelines \(for Community Health Centers\)](#)
- [CAIR Requirement for Documenting 317-Funded Vaccines](#)

#### 2023-24 COVID-19 Vaccine Information

Please see EZIZ's [COVID-19 Vaccine Resources](#) for vaccine administration job aids plus materials from FDA, CDC and vaccine manufacturers.

[Eligibility Cheat Sheet](#)

[Step-by-step Instructions](#)  
(includes options for reporting to CAIR)

[Screening Record](#)  
(for small practices with no EHR)

[BAP Resources](#)



# BAP Communications and Listservs

- Email Blanca Corona at [Blanca.Corona@cdph.ca.gov](mailto:Blanca.Corona@cdph.ca.gov) to subscribe to the COVID-19 Vaccine Listserv or to receive help with troubleshooting.
- View [archived communications](#).
- Make sure you mark [ProviderCallCenter@cdph.ca.gov](mailto:ProviderCallCenter@cdph.ca.gov) as a “**safe sender**” on your email account to prevent communications from redirecting to your spam, junk, or other folder.
- **New BAP Listserv:** Providers, MCEs, and LHDs who are subscribed to the COVID-19 vaccine Listserv have been **automatically subscribed** to our new BAP Listserv, which went live earlier this week.



# CDPH Provider Webinars and Trainings








Week of September 18, 2023

	Monday 9/18	Tuesday 9/19	Wednesday 9/20	Thursday 9/21	Friday 9/22
<b>Live Webinars and Training</b>	<a href="#">My Turn and myCAvax Office Hours</a> 12:00 pm – 1:00 pm	<a href="#">CDC COCA Call: Preparing for the Upcoming Respiratory Virus Season: Recommendations for Flu, COVID-19, and RSV Vaccines for Older Adults</a> 11:00 am – 12:00 pm			<a href="#">COVID-19 Weekly Provider Webinar Series</a> 9:00 am – 10:30 am
<b>View On Demand</b>	<ul style="list-style-type: none"> <li><a href="#">Intro to My Turn Onboarding (v. 1/4/22)</a></li> <li><a href="#">Latest Features in My Turn (Requires My Turn Login)</a></li> <li><a href="#">CDPH Weekly Provider Webinars Archived Recordings and Slides</a></li> </ul>		<ul style="list-style-type: none"> <li><a href="#">myCAvax Release Notes for LHJs and CDPH Users (Requires myCAvax Login)</a></li> <li><a href="#">Latest Features in myCAvax for Providers (Requires myCAvax Login)</a></li> <li><a href="#">COVID-19 Crucial Conversations Archived Webinars and Slides</a></li> </ul>		<ul style="list-style-type: none"> <li><a href="#">Moderna COVID-19 Vaccine Resources for Providers</a></li> <li><a href="#">CDC COVID-19 Vaccine Webinar Series</a></li> <li><a href="#">California Immunization Coalition COVID Conversation Series</a></li> <li><a href="#">AIM Vaccine Confidence Toolkit Webinar Series</a></li> </ul>
<b>Help</b>	<b>Help Desk</b> myCAvax Help Desk Email: <a href="mailto:mycavax.hd@cdph.ca.gov">mycavax.hd@cdph.ca.gov</a> My Turn Help Desk Email: <a href="mailto:myturn.clinic.hd@cdph.ca.gov">myturn.clinic.hd@cdph.ca.gov</a> My Turn Onboarding Email: <a href="mailto:myturnonboarding@cdph.ca.gov">myturnonboarding@cdph.ca.gov</a>		<b>General</b> CDPH Provider Call Center: 1-833-502-1245, 8am-5pm, Mon-Fri Email: <a href="mailto:providercallcenter@cdph.ca.gov">providercallcenter@cdph.ca.gov</a> Vaccines: <a href="#">COVID-19 Vaccines</a> Therapeutics: <a href="#">COVID-19 Therapeutics</a>		<b>Mpox</b> Email: <a href="mailto:stdcb@cdph.ca.gov">stdcb@cdph.ca.gov</a> General Website: <a href="#">Mpox Website</a> Vaccines: <a href="#">Mpox Vaccines Website</a>






# COVID-19 Therapeutics Resources

Type of Support	Description	Updated 9.11.23
 <b>Clinical Guidance</b>	COVID-19 Therapeutics Warmline: <a href="tel:1-866-268-4322">1-866-268-4322 (866-COVID-CA)</a> Monday through Friday 6 am – 5 pm. Messages left after hours will be returned on the next business day.	
 <b>General Information</b>	<a href="#">CDPH COVID-19 Treatments Webpage</a> (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources) <a href="#">CDPH COVID-19 Treatments Job Aid</a> (questions and answers for the public on COVID-19 therapeutics) <a href="#">COVID-19 Therapeutics Best Practices Checklist</a> (testing, prescribing, dispensing, and more) <a href="#">Frequently Asked Questions document</a> for clinics, providers, and pharmacists	
 <b>Locating Resources</b>	Finding Providers and Test-to-Treat Sites <ul style="list-style-type: none"><li>• <a href="#">COVID-19 Therapeutics Locator</a> (arcgis.com)</li><li>• <a href="#">Test-to-Treat</a> (hhs.gov)</li></ul>	
 <b><u>LHJ Therapeutics SharePoint</u></b>	Primary source for recorded webinars, slides, datasets and <u>HPoP</u> reporting information. (For access, email <a href="mailto:JEOCuser54@cdph.ca.gov">JEOCuser54@cdph.ca.gov</a> ) <ul style="list-style-type: none"><li>• <a href="#">Archived Therapeutic Weekly Webinar Files</a> (Meeting Presentations, Recordings, &amp; Q&amp;A)</li><li>• <a href="#">Archived Therapeutic Weekly Email Update for 2023</a> files (SharePoint)</li></ul>	
 <b>Questions</b>	For general CDPH Therapeutics questions, please email <a href="mailto:COVIDRxProviders@cdph.ca.gov">COVIDRxProviders@cdph.ca.gov</a> For ordering, program inquiries, signing up new <u>HPoP</u> Accounts: please e-mail <a href="mailto:CDPHTherapeutics@cdph.ca.gov">CDPHTherapeutics@cdph.ca.gov</a>	

# Questions

**During today's session, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.**



**Resource links will be dropped into, “Chat”**

# Upcoming Opportunities



## Monday - FINAL SESSION

### My Turn and myCAvax Office Hours

Next session: Monday, September 18, 12PM-1PM

## Friday

### Provider Consolidated Webinar

Next session: Friday, September 22, 9AM-10:30AM

